: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00
: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns. buy pfizer stock
Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation: : The success of Pfizer's $43 billion Seagen
AI responses may include mistakes. For financial advice, consult a professional. Learn more Management has reaffirmed its commitment to the dividend,
: To offset the loss of exclusivity (LOE) on blockbusters like Eliquis and Ibrance, Pfizer is aggressively reinvesting in oncology and obesity. Key 2026 catalysts include the start of 20 pivotal clinical trials , notably in the high-growth GLP-1 (obesity) market and next-generation cancer therapies. Key Risks and Headwinds
As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500.
